Table 2.
Clinicopathologic factors related to CXCR4 expression in 181 HCC patients
| CXCR4 Expression | ||||
|---|---|---|---|---|
| Clinicopathologic Parameters | No. of Cases | Negative (n = 90) | Positive (n = 91) | P |
| Age (y) | ||||
| ≤ 60 | 153 | 76 (49.7%) | 77 (50.3%) | 0.975 |
| > 60 | 28 | 14 (50.0%) | 14 (50.0%) | |
| Gender | ||||
| Female | 25 | 16 (64.0%) | 9 (36.0%) | 0.124 |
| Male | 156 | 74 (47.4%) | 82 (52.6%) | |
| HBsAg | ||||
| Negative | 37 | 22 (59.5%) | 15 (40.5%) | 0.184 |
| Positive | 144 | 68 (47.2%) | 76 (52.8%) | |
| AFP(ng/mL, mean ± SD) | 181 | 4941.25 ± 13475.41 | 3375.54 ± 11340.86 | 0.396 |
| ≤ 20 | 48 | 18 (37.5%) | 30 (62.5%) | 0.017* |
| 20 – 400 | 59 | 26 (44.1%) | 33 (55.9%) | |
| ≥ 400 | 74 | 46 (62.2%) | 28 (37.8%) | |
| Cirrhosis | ||||
| Absence | 45 | 22 (48.9%) | 23 (51.1%) | 0.897 |
| Presence | 136 | 68 (50.0%) | 68 (50.0%) | |
| Satellite lesion | ||||
| Absence | 127 | 65 (51.2%) | 62 (48.8%) | 0.548 |
| Presence | 54 | 25 (46.3%) | 29 (53.7%) | |
| Tumor size (cm) | 181 | 6.15 ± 3.66 | 6.75 ± 3.28 | 0.247 |
| Margins | ||||
| Clear | 79 | 45 (57.0%) | 34 (43.0%) | 0.087 |
| Involved | 102 | 45 (44.1%) | 57 (55.9%) | |
| Vascular invasion | ||||
| Absence | 95 | 44 (46.3%) | 51 (53.7%) | 0.335 |
| Presence | 86 | 46 (53.5%) | 40 (46.5%) | |
| Portal Vein Thrombosis | ||||
| Absence | 153 | 72 (47.1%) | 81 (52.9%) | 0.094 |
| Presence | 28 | 18 (64.3%) | 10 (35.7%) | |
| Hilar Lymph Nodes | ||||
| Absence | 170 | 89 (52.4%) | 81 (47.6%) | 0.005* |
| Presence | 11 | 1 (9.1%) | 10 (90.9%) | |
| UICC T stage | ||||
| T1 | 91 | 45 (49.5%) | 46 (50.5%) | 0.693 |
| T2 | 38 | 17 (44.7%) | 21 (55.3%) | |
| T3 | 52 | 28 (53.8%) | 24 (46.2%) | |
| Edmondson grade | ||||
| Low (I/II) | 118 | 61 (51.7%) | 57 (48.3%) | 0.468 |
| High (III/IV) | 63 | 29 (46.0%) | 34 (54.0%) | |
| Bone Metastases | ||||
| Absence | 138 | 81 (58.7%) | 57 (41.3%) | < 0.001* |
| Presence | 43 | 9 (20.9%) | 34 (79.1%) | |
* Significant P value.